# Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics

> **NCT02169414** · PHASE1 · COMPLETED · sponsor: **Bial - Portela C S.A.** · enrollment: 74 (actual)

## Conditions studied

- Parkinson's Disease (PD)

## Interventions

- **DRUG:** BIA 9-1067 5 mg
- **DRUG:** BIA 9-1067 25 mg
- **DRUG:** levodopa/carbidopa 100/25
- **DRUG:** Placebo
- **DRUG:** levodopa/benserazide 100/25 mg

## Key facts

- **NCT ID:** NCT02169414
- **Lead sponsor:** Bial - Portela C S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2015-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02169414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02169414, "Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02169414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*